Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AURA
SELLAura Biosciences, Inc. · Healthcare · United States · $729M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Aura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs) for the treatment of ocular oncology. Its lead product candidate, belzupacap sarotalocan (AU-011), is being developed for ocular melanoma, a rare and aggressive eye cancer. The company's innovative VDC platform represents a novel approach to targeted cancer therapy, addressing unmet medical needs in underserved indications.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | 7.7M | — |
| EPS | -8.95 | -0.72 | -0.92 | -0.85 | -1.76 | — | -1.67 | -1.59 | -1.67 | — |
| Shares | 29.2M | 103.4M | 103.4M | 103.4M | 63.6M | +117.7% | — | — | — | — |
| Debt | 1.0M | 20.9M | 19.6M | 18.8M | 17.4M | 105.5% | 17.0M | — | — | — |
| Equity | 152.3M | 195.6M | 225.8M | 152.0M | 136.9M | -2.6% | — | — | — | — |
| Op CF | -32.4M | -54.6M | -63.8M | -79.8M | -84.7M | — | -91.3M | — | — | — |
| Inv CF | -2.1M | -67.9M | -114.0M | 68.8M | 35.6M | — | — | — | — | — |
| Fin CF | 166.3M | 95.6M | 97.3M | 1.6M | 77.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AURA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AURA | Aura Biosciences, Inc.(you) | $729M | 23 | SELL |
| DRUG.CN | Bright Minds Biosciences Inc. | $727M | 24 | SELL |
| SLDB | Solid Biosciences Inc. | $771M | 24 | SELL |
| DSGN | Design Therapeutics, Inc. | $736M | 25 | SELL |
| ANL | Adlai Nortye Ltd. | $805M | 24 | SELL |
| ACRS | Aclaris Therapeutics, Inc. | $730M | 20 | SELL |
| STTK | Shattuck Labs, Inc. | $710M | 27 | SELL |
| OMER | Omeros Corporation | $709M | 27 | SELL |
| NVCT | Nuvectis Pharma, Inc. | $609M | 25 | SELL |
| CBIO | Crescent Biopharma, Inc. | $602M | 25 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%